Evolving strategies in the management of diabeticmacular edema: Clinicaltrials and current management

Canadian Journal of Ophthalmology

Volumn 48, Issue 1, 2013, Pages 22-30

  Thomas, Benjamin J ^a   Shienbaum, Gary ^a   Boyer, David S ^a,b   Flynn, Harry W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CONFERENCE PAPER; DIABETIC MACULAR EDEMA; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LOW LEVEL LASER THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; VISUAL ACUITY;

EID: 84875479209     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.11.012     Document Type: Conference Paper

References (25)

1. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol. 2012;57:347-70.
2. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130:1145-52.
3. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. CurrMed Res Opin. 2010;26:1587-97.
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-806.
5. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-9.
6. Nguyen QD, Shah SM, Heier JS, et al. READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2009;116:2175-81.
7. Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology. 2010;117:2146-51.
8. Do DV, Campochiaro PA, Boyer DS, et al READ 3 Research Group; Six-month and one-year interim results of the READ 3 study: Ranibizumab for Edema of the mAcula in Diabetes. Abstract presented at: 2012 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); May 9, 2012; Fort Lauderdale, Fla.
9. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12- month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-405.
10. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-25.
11. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
12. Boyer DS, Rundle AC, Zhang J, Hopkins JJ, Ehrlich JS. Long term efficacy and safety of ranibizumab in diabetic macular edema (DME): 36-month results from RISE and RIDE, two phase III clinical trials. Presented at: 45th Annual Scientific Meeting of the Retina Society; October 5, 2012; Washington, D.C.
13. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-77.
14. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119:2312-8 http://dx.doi.org/10.1016/j.ophtha.2012.08.022.
15. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117:1078-86.
16. Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249:15-27.
17. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24- month data: report 3. Arch Ophthalmol. 2012;130:972-79.
18. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118:1819-26.
19. Do DV, Nguyen QD, Boyer D, et al. DA VINCI Study Group. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119: 1658-1665.
20. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447-9.
21. Campochiaro PA, Brown DM, Pearson A, et al. FAME Study Group. Long-term benefit of sustained-delivery fluocinolone acet- onide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118:626-35.
22. Campochiaro PA, Brown DM, Pearson A, et al. FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125-32.
23. Callanan D, Gupta S, Ciulla TA, et al. Efficacy and safety of combination therapy with dexamethasone intravitreal implant (DEX implant) plus laser photocoagulation versus monotherapy with laser for treatment of diffuse diabetic macular edema (DDME). Abstract presented at: 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology; May 4, 2011; Fort Lauderdale, Fla.
24. Boyer DS, Faber D, Gupta S, et al. Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina. 2011;31: 915-923.
25. Clinicaltrials.gov. Diabetic Retinopathy Clinical Research Network. Comparative Effectiveness Study of Intravitreal Aflibercept, Bev- acizumab, and Ranibizumab for DME.ClinicalTrial.gov Identifier NCT01627249. clinicaltrials.gov/ct2/show/NCT01627249.